Navigation Links
Anesiva to Unveil Zingo(TM) Commercialization Plans

SOUTH SAN FRANCISCO, Oct 4 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it will host a briefing for the investment community to review the company's launch and commercialization plans for Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system. The briefing will take place on Friday October 12, 2007 from noon to 1:30 p.m. Eastern Time in New York City. To access the live audio broadcast or the subsequent archived recording, please visit

Anesiva's management and will review the company's manufacturing and commercialization plans as well as the timeline for the Zingo launch. The meeting will also feature William T. Zempsky, M.D., a pediatric pain specialist and associate professor of Pediatrics and Emergency Medicine at the University of Connecticut School of Medicine, who will discuss clinical experience with Zingo and the role it can play in pediatric medicine.

About Zingo

Zingo is a ready-to-use, single-use, needle-free system that delivers sterile lidocaine powder into the epidermis of the skin and provides topical, local analgesia in one to three minutes after administration. This rapid onset, which may be especially useful in pediatric populations and busy emergency room settings, means the product can be incorporated into a medical procedure allowing uninterrupted care, an important advantage over current options. In addition to the hospital setting, Zingo may be used in physicians' offices and clinical laboratories. Anesiva also recently completed enrollment of a Phase 3 trial evaluating Zingo in adults with the goal of expanding the label beyond the pediatric population.

About Anesiva and its Diverse Portfolio of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has one FDA-approved product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, to reduce pain associated with peripheral venous access procedures in children three to 18 years of age. The second product in Anesiva's pipeline, Adlea(TM) (formerly 4975), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
2. Canine Painkiller unveiled by Novartis
3. Skin cancers secrets unveiled
4. Pfizer unveils anti-smoking drug
5. WHO and UNAIDS unveil plan to get 3 million AIDS patients on treatment by 2005
6. Scientists Unveil Mechanism Behind Resistance to Severe Malaria
7. Study Unveils New Insight To The Madness Of King George III
8. Bush Unveils Latest Blueprint for Handling Bird Flu Pandemic
9. Rae unveils Health-care Strategy
10. Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development
11. New Health Insurance Scheme for Diabetics Unveiled
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ... raise to $12 an hour by 2020 and then adjusting it yearly to increase at ... the minimum wage, assure the wage floor does not erode again, and make future increases ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... -- VMS Rehab Systems, Inc. ( ) reported today ... to build a strong and stable market for trading ... the OTC Markets-pink current trading platform. Explains ... seeing an anomaly in market trading activities that may ... Company, but shareholders and market players as well. I ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology: